Orchard Therapeutics Plc ADR (ORTX)

$16.70 0.00 (0.00%)

16:00 EST ORTX Stock Quote Delayed 30 Minutes

Why Is Orchard Therapeutics (ORTX) Stock Up 98% Today?

By William White, InvestorPlace Writer Oct 5, 2023

Orchard Therapeutics stock is rising higher on Thursday as Kyowa Kirin agrees to acquire ORTX shares for $16 each in a $387.4 million deal.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

More Articles

Volume:

Previous Close -

Market Cap 3.08B

PE Ratio -139.17

EPS -0.12

Volume (Avg. Vol.)

Day's Range -

52-Week Range $4.80 - $16.70

Dividend & Yield N/A (N/A)

ORTX Stock Predictions, Articles, and Orchard Therapeutics Plc ADR News

From InvestorPlace
From the Web

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer May 12, 2021

We're back at it again with a look at the biggest pre-market stock movers for Wednesday and it's clear earnings season is here.

ORTX Stock Alert: 8 Things to Know About Gene Therapy Play Orchard Therapeutics

By William White, InvestorPlace Writer Jan 6, 2021

Orchard Therapeutics (ORTX) stock is on the rise Wednesday with heavy trading even with there being no major news about the company.

4 IPOs to Watch This Week

By Tom Taulli, InvestorPlace Contributor Oct 29, 2018

There are four IPOs this week -- all small biotechs. But because of market turblence, it could be a tough environment for these offerings.

Orchard Therapeutics gains FDA fast track status for Hurler syndrome therapy (NASDAQ:ORTX)

From Seeking Alpha Nov 30, 2023

Orchard Therapeutics receives FDA Fast Track Designation for its gene therapy to potentially treat Hurler subtype of mucopolysaccharidosis type I (MPS-IH).

Orchard says no FDA AdCom on gene therapy (NASDAQ:ORTX)

From Seeking Alpha Nov 21, 2023

Orchard Therapeutics (ORTX) says the FDA won't hold an AdCom meeting as part of a review for its gene therapy Libmeldy for metachromatic leukodystrophy. Read more here.

Orchard Therapeutics GAAP EPS of -$0.15 beats by $0.30, revenue of $6.3M misses by $1.6M (NASDAQ:ORTX)

From Seeking Alpha Nov 13, 2023

Orchard Therapeutics reports Q3 financial results. Despite beating earnings estimates, revenue falls short, raising concerns for investors.

Why Orchard Therapeutics Stock Is Soaring Today

From The Motley Fool Oct 5, 2023

A buyout offer is fueling a rise in the company's shares today.

Biggest stock movers today: BlackBerry, Clorox, Rivian Automotive and more (NYSE:BB)

From Seeking Alpha Oct 5, 2023

Stock futures inched lower in premarket activity on Thursday as market participants await key jobs data. Here are some of Thursday's biggest stock movers in pre

Orchard Therapeutics: Q1 Earnings Insights

From Benzinga May 12, 2022

Orchard Therapeutics (NASDAQ:ORTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

ADVERTISEMENT